Answers are grounded in this paper and cite their sources.
With the increased time of survival as a result of improved prophylaxis and treatment of AIDS, non-infectious conditions related to HIV are being detected more frequently. In addition to the well-known myocarditis and cardiomyopathy, pulmonary hypertension represents another HIV-induced cardiovascular complication with a very poor prognosis: The median time interval between the diagnosis of pulmonary hypertension in HIV patients and death is only 6 months [1]. The pathophysiology of HIV-related pulmonary hypertension is still unknown. As histopathology shows similarities to primary pulmonary hypertension and because no direct virus presence in the pulmonary endothelium was found, it has been suggested that HIV-induced mediator and growth factor-related inflammatory reactions altering the pulmonary cell homeostasis might be the cause of this cardiovascular condition. Therapy is based on antiretroviral medication and the substances used in primary pulmonary hypertension, such as pulmonary vasodilators. No treatment of choice for HIV-related pulmonary hypertension has been defined up to now [1]. Two HIV-positive patients were evaluated for a history of worsening dyspnoea during exercise. Patient 1, a 41-year-old man, was first diagnosed with AIDS in 1983, his current CD4 cell count was 236 cells/mm3. Patient 2, a 38-year-old woman, had been HIV infected for 15 years. Her CD4 cell count was above 500 cells/mm3. Both patients contracted HIV through intravenous drug abuse. No signs of opportunistic infections had been present. Clinical examination and diagnostic imaging techniques showed the typical changes of pulmonary hypertension: Chest radiograph indicated prominent hili, and thoracic computed tomography scan revealed a marked increase in pulmonary vessel diameter. Echocardiographic findings included increased diameters of the right atrium and right ventricle, a flattened septum and a tricuspidal pressure gradient of 38 mmHg (patient 1) and 48 mmHg (patient 2). Right heart catheterization showed increased pulmonary pressures in both patients (Fig. 1). As other reasons for pulmonary hypertension were ruled out by additional investigations, the patients were diagnosed with HIV-related pulmonary hypertension.Fig. 1.: Pulmonary arterial pressures in two patients with HIV-related pulmonary hypertension before and after oral administration of 50 mg sildenafil. Patient 1, dotted line; patient 2, full line; ▵ systolic pulmonary arterial pressure; ○ mean pulmonary arterial pressure; × diastolic pulmonary arterial pressure.Other investigations [2] revealed a dose-related decrease of pulmonary pressures after the administration of sildenafil (Viagra) to pulmonary hypertensive lambs. In addition, it has been demonstrated in vitro that sildenafil, as a specific inhibitor of the phosphodiesterase isoform, PDE 5, might lead to smooth muscle relaxation via a nitric oxide-dependent increase of cyclic guanosine 5-monophosphate [3]. PDE 5 is found in high concentrations in lung tissue, and its inhibition by sildenafil might reduce pulmonary vascular pressures by this pathway. With this mechanism in mind and in view of the poor prognosis of HIV-related pulmonary hypertension with the lack of a treatment of choice, both patients were administred 50 mg oral sildenafil under continous monitoring of pulmonary arterial pressures (Swan–Ganz thermodilution catheter, Edwards Laboratories Inc., Edwards Lifesciences, Irvine, CA, USA). The results are shown in Fig. 1. Before sildenafil administration, both patients showed moderate pulmonary hypertension. Within 2 h after application, pulmonary arterial pressures dropped significantly by 20% (patient 1) and 22% (patient 2) of the initial values. Whereas patient 2 showed a graded return to pre-sildenafil values within 9 h, the pulmonary pressures of patient 1 remained significantly lowered up to 9 h after administration. No side-effects were observed during the study period. The levels of decrease of pulmonary pressures in our investigation was similar to those observed during animal testing. Other authors proposed sildenafil as a potential treatment for primary pulmonary hypertension in children and adults [4,5]. With these findings in mind, patient 1 was subsequently started on an oral therapy, consisting of 50 mg sildenafil twice a day. Standardized echocardiographic follow-up to monitor pulmonary arterial pressures was performed on a regular basis over 3 months. The echocardiographic data showed a persisting decrease of 20% of the estimated pulmonary arterial pressure under sildenafil administration during the observation period. The clinical condition of the patient was markedly improved: Dyspnoea had resolved and exercise capacity was improved. Our data suggest that sildenafil might be evaluated as a beneficial treatment for patients with HIV-related pulmonary hypertension. Prospective studies are nescessary to confirm these findings. Annemarie M. C. van Rossum Jeanne P. Dieleman Pieter L. A. Fraaij Karlien Cransberg Nico G. Hartwig Inge C. Gyssens Ronald de Groot Yorck O.
No takes yet. Share an insight, caveat, or question.
Schumacher et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: